



## Macrophages of distinct origins contribute to tumor development in the lung

Pierre-Louis Loyher, Pauline Hamon, Marie Laviron, Aïda Meghraoui-Kheddar, Elena Goncalves, Zihou Deng, Sara Torstensson, Nadège Bercovici, Camille Baudesson De Chanville, Béhazine Combadière, et al.

### ► To cite this version:

Pierre-Louis Loyher, Pauline Hamon, Marie Laviron, Aïda Meghraoui-Kheddar, Elena Goncalves, et al.. Macrophages of distinct origins contribute to tumor development in the lung. *Journal of Experimental Medicine*, 2018, 215 (10), pp.2536 - 2553. 10.1084/jem.20180534 . hal-01913815

**HAL Id: hal-01913815**

**<https://hal.science/hal-01913815>**

Submitted on 6 Nov 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Macrophages of distinct origins contribute to tumor development in the lung

Pierre-Louis Loyher<sup>1,4\*</sup>, Pauline Hamon<sup>1\*</sup>, Marie Laviron<sup>1</sup>, Aïda Meghraoui-Kheddar<sup>1</sup>, Elena Goncalves<sup>1</sup>, Zihou Deng<sup>4</sup>, Sara Torstensson<sup>1</sup>, Nadège Bercovici<sup>2</sup>, Camille Baudesson de Chanville<sup>1</sup>, Béhazine Combadière<sup>1</sup>, Frederic Geissmann<sup>4</sup>, Ariel Savina<sup>3</sup>, Christophe Combadière<sup>1</sup> and Alexandre Boissonnas<sup>1</sup>.

<sup>1</sup> Sorbonne Université, Institut universitaire de cancérologie (IUC), Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses CIMI, F-75013, Paris, France.

<sup>2</sup>Inserm, U1016, Institut Cochin, CNRS UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

<sup>3</sup>Institut Roche, 30, Cours de l'Île Seguin, 92650 Boulogne-Billancourt Cedex, France.

<sup>4</sup>Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

Corresponding author: alexandre.boissonnas@upmc.fr

\*P.L. and P.H. are co-first authors

## Non-standard abbreviations:

TAM: Tumor-associated macrophage

Res-TAMs: Tissue-resident macrophages

MoD-TAMs: Monocyte derived macrophages

PyMT-Chova: MMTV PyMT-P2A-mCherry-P2A-OVA mice

OH-TAMs: 4-hydroxytamoxifen

AM: Alveolar macrophage

IM: Interstitial macrophage

Mo: Monocyte

CP: Cyclophosphamide

TME: Tumor-microenvironment

## **Abstract**

Tissue-resident macrophages can self-maintain without contribution of adult hematopoiesis. Herein we show that tissue-resident interstitial macrophages (Res-TAMs) in mouse lungs contribute to the pool of tumor-associated macrophages (TAMs) together with CCR2-dependent recruited macrophages (MoD-TAMs). Res-TAMs largely correlated with tumor cell growth *in vivo* while MoD-TAMs accumulation was associated with enhanced tumor spreading. Both cell subsets were depleted after chemotherapy, but MoD-TAMs rapidly recovered and carried out phagocytosis-mediated tumor clearance. Interestingly, anti-VEGF treatment combined with chemotherapy inhibited both Res and Mod-TAM reconstitution without affecting monocyte infiltration and improved its efficacy. Our results reveal that the developmental origin of TAMs dictates their relative distribution, function and response to cancer therapies in lung tumors.

## Introduction

The tumor-microenvironment (TME) can regulate malignant potential and contributes to tumor heterogeneity. Tumor-associated macrophages (TAMs) are the most abundant host cells within the TME (Qian and Pollard, 2010) and have been implicated in the promotion of invasiveness (Wyckoff et al., 2007), growth (Pollard, 2004), angiogenesis (Lewis et al., 2016), metastasis (Kitamura et al., 2015) and immunosuppression (Boissonnas et al., 2013; Broz et al., 2014). TAMs have been suggested to limit the efficacy of chemotherapeutic agents and to promote tumor relapse (Hughes et al., 2015), although they can in some cases be required for optimal therapy response (De Palma and Lewis, 2013).

It is considered that TAMs mainly arise from the differentiation of monocytic precursors (Cortez-Retamozo et al., 2012; Franklin et al., 2014). However, in many tissues, pools of resident macrophages have been identified; these originate from embryonic precursors and self-maintain independently of hematopoietic stem cells (Gomez Perdiguero et al., 2015). Distinct transcriptional programs initiated in embryonic, fetal or adult progenitors (Mass et al., 2016) and the exposure to specific tissue environments (Gosselin et al., 2014; Lavin et al., 2014) may explain the specialization and diversity of macrophages in healthy as well as neoplastic tissues. The lung environment is densely colonized by subsets of mononuclear phagocytic cells displaying various spatial organizations, functions and dependence for blood monocytes in their maintenance. Interstitial macrophages (IMs) represent a discrete population in the steady state lung largely outnumbered by alveolar macrophages (AMs) (Gibbins et al., 2017; Rodero et al., 2015). IMs and AMs express different surface markers which allow their identification and they have been described to arise from distinct developmental waves without interconverting (Guilliams et al., 2013; Tan and Krasnow, 2016).

So far, the contribution of these different resident macrophage subsets in the generation of lung TAMs has not been reported.

Herein, the TAM network in lung tumors was studied based on transgenic fluorescent reporter mice and fate mapping models that enable the discrimination of the lung mononuclear phagocyte subsets according to their origin and localization. We showed that the TAM compartment is intermingled by both yolk sac-derived interstitial and monocyte-derived recruited macrophages, differentially represented in the TME depending on the anatomical site of tumor development in the lung. Finally, we highlight their respective implication on lung tumor development and response to various anti-cancer therapies.

## Results

### Lung macrophage subsets differentially accumulate during tumor development

We studied the impact of tumor growth on the different subset of lung myeloid cells after inoculating TC-1 lung carcinoma cells, which induce multifocal tumor nodules (Ji et al., 1998; Lin et al., 1996). The tumor-associated myeloid signature was monitored along tumor evolution using flow cytometry phenotyping combined with a non-supervised viSNE analysis. The generated tSNE-plot was calculated with 12 parameters including cell anatomic distribution between the tissue parenchyma and the vasculature. This distinction is achievable using anti-CD45 antibody injected intravenously that allows a blood/tissue partitioning of cells (see dashed gates **Figure 1A and S1**). Ten clusters obtained using unsupervised analysis were subsequently assigned to a specific cell population according to expression level of each marker and previously described phenotypes (Gibbins et al., 2017; Misharin et al., 2013; Sabatel et al., 2017) (**Figure S1A**). Briefly, cluster 7 and cluster 8 were identified as classical  $\text{Ly6C}^{\text{high}}$  and non-classical  $\text{Ly6C}^{\text{low/-}}$  monocytes (Mo) respectively, with  $\text{CD11b}^{\text{high}}\text{Siglec-F}^{\text{low}}\text{Ly6G}^{\text{low}}\text{Fc-gamma receptor 1}^{\text{low}} (\text{CD64}^{\text{low}})$  expression profile. Cluster 2 included  $\text{CD11b}^{\text{low}}\text{CD11c}^{\text{high}}\text{Siglec-F}^{\text{high}}$  cells, representing alveolar macrophages (AMs), while cluster 1 included  $\text{CD11b}^{\text{high}}\text{Siglec-F}^{\text{low}}\text{Ly6G}^{\text{low}}\text{CD64}^{\text{high}}$  cells representing a distinct subset of lung macrophages named here  $\text{Ly6C}^{\text{low/-}}\text{CD64}^{\text{high}}$  Mac. These different macrophage subsets were clearly distinguished from cluster 3, identified as  $\text{CD11b}^{\text{low}}\text{I-A[b]}^{\text{high}}\text{CD11c}^{\text{low}}\text{CD103}^{\text{low}}\text{Ly6C}^{\text{low}}\text{CD64}^{\text{low}}$  cells and cluster 5 identified as  $\text{CD11b}^{\text{low}}\text{I-A[b]}^{\text{high}}\text{CD11c}^{\text{low}}\text{Ly6C}^{\text{low}}\text{CD64}^{\text{low}}$  cells known as conventional dendritic cells cDC1 and cDC2 respectively. Cluster 6 and 9 are defined as  $\text{CD11b}^{\text{high}}\text{Ly6G}^{\text{high}}$  cells (representing two subsets of neutrophils with differential expression of CD24). Cluster 10 represented  $\text{CD11b}^{\text{high}}\text{Siglec-F}^{\text{int}}$  cells identified as eosinophils (**Figure 1A, S1A-B**). In the absence of tumor,  $\text{Ly6C}^{\text{high}}$ -Mo (cluster 7) and  $\text{Ly6C}^{\text{low/-}}$ -Mo (cluster 8) resided almost exclusively within lung vessels whereas AMs (cluster 2) and  $\text{Ly6C}^{\text{low/-}}\text{CD64}^{\text{high}}$  Mac (cluster 1) were detected in the lung parenchyma only (**Figure 1A and S1C**). With tumor expansion, cluster 4 including  $\text{Ly6C}^{\text{high}}\text{CD64}^{\text{high}}$  cells appeared together with a progressive and

massive accumulation of Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac (cluster 1) (**Figure 1A**). Supervised analysis of Ly6C, CD64 expression and intravascular cell labeling on CD11b<sup>+</sup>Siglec-F<sup>-</sup>Ly6G<sup>-</sup> gated cells suggested that Ly6C<sup>high</sup>-Mo progressively upregulate CD64 and differentiate into Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac upon tumor infiltration (**Figure S1C-D**). In contrast, Ly6C<sup>low/-</sup>-Mo did not apparently accumulate and they remained mostly intravascular (**Figure 1 and S1**). Blood/tissue partitioning of monocyte and macrophage subsets (**Figure 1C-D**) was next performed using supervised analysis and the observations made on tSNE plots were confirmed. While the Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac subset massively accumulated in the tumor parenchyma exclusively, the number of AMs per mg of tissue strongly diminished with tumor growth, leading to 50% reduction in their number per whole lungs after 20 days (**Figure 1B**). Overall, these observations suggest that monocyte-derived macrophages (MoD-Mac) and lung-resident macrophages might differentially contribute to the tumor microenvironment.

### **Macrophages have distinct origins within lung tumors**

We previously demonstrated that the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mouse can be used to discriminate monocyte and macrophage subsets in lungs according to their relative expression of the ECFP and EGFP fluorescent reporters (Rodero et al., 2015). Histological analysis of TC1<sup>tdTomato</sup> tumor-bearing mice along tumor expansion unveiled that tumor nodules were infiltrated by distinct cell subsets expressing EGFP and ECFP (**Figure 2A, S2A**). The fluorescent signatures of monocytes and macrophages in tumor-free and tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice were compared using tSNE algorithm and clusters were assigned as previously described (**Figure S2B**). Briefly, classical Ly6C<sup>high</sup> (cluster 4) and non-classical Ly6C<sup>low/-</sup> (cluster 6) monocyte subsets both expressed high level of ECFP and respectively low and high levels of EGFP according to their relative expression of the *Cx3cr1* gene reporter. AMs (cluster 1) expressed high level of ECFP but no EGFP (**Figure S2C**). Interestingly, the Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac subset was distributed between clusters 2 and 3 suggesting different cell origin in this subset. In tumor-free animals, cluster 3 was dominant and was mainly composed of EGFP<sup>high</sup> ECFP<sup>neg</sup> (named EGFP<sup>+</sup> macrophages, representing

87±4.2% of the total Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac) (**Figure S2D**). We previously observed that this subset typically represents interstitial macrophages (IMs) located in the pleura, along blood vessels and nearby large airways of the lungs (Rodero et al., 2015). Following tumor inoculation, cluster 2 including Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac subset, expressing high level of ECFP and EGFP (named ECFP<sup>+</sup> macrophages), accumulated along with cluster 3 but became dominant as soon as day 10 (70.4±9.8% of the Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac) (**Figure S2**).

The reduction of AMs was confirmed in the second tSNE signature (cluster 1) (**Figure S2B**). Co-labeling of MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice with Siglec-F on histological sections showed that ECFP<sup>+</sup>Siglec-F<sup>+</sup> AMs remained exclusively localized in the healthy alveolar space, outside tumor nodules (**Figure S2E**), suggesting that AMs are progressively eliminated during tumor expansion or that they completely change their phenotype. We thus hypothesized that tumor development leads to the accumulation of lung tumor-associated macrophages (TAMs) from distinct origins. To address this, the distribution of EGFP<sup>+</sup> or ECFP<sup>+</sup> cells was analyzed in tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> x *Ccr2*<sup>-/-</sup> mice. ECFP<sup>+</sup> macrophages were substantially reduced in *Ccr2*<sup>-/-</sup> mice whereas EGFP<sup>+</sup> macrophages and AMs were unaffected (**Figure 2B**). This suggests a monocytic origin of ECFP<sup>+</sup> macrophages while EGFP<sup>+</sup> macrophage accumulation is CCR2-independent. Macrophage distribution was next compared on histological lung sections of tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> (WT), MacBlue x *Cx3cr1*<sup>EGFP/+</sup> x *Ccr2*<sup>-/-</sup> (*Ccr2*<sup>-/-</sup>), and C57Bl6 host parabiont with the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> donor mouse. In pulmonary nodules of WT mice, the ratio of ECFP<sup>+</sup>/EGFP<sup>+</sup> cells was 0.57±0.10 whereas the corresponding ratio was 0.14±0.08 in *Ccr2*<sup>-/-</sup> mice and 0.96±0.07 in host parabiont mice (**Figure 2C**). These results support that TAMs in lung tumors are composed of both ECFP<sup>+</sup> monocyte-derived macrophages (ECFP<sup>+</sup>-TAMs) and a CCR2-independent local accumulation of EGFP<sup>+</sup> resident interstitial macrophages (EGFP<sup>+</sup>-TAMs).

These two fluorescent subsets were also present within lewis lung carcinoma (LLC) nodules with similar proportion. ECFP<sup>+</sup>/EGFP<sup>+</sup> cells ratio within nodules was 0.65±0.03 on histological sections, among which ECFP<sup>+</sup> TAMs represented 58±8.5% of total TAMs as depicted by



flow cytometry analysis (**Figure 2D**). We next evaluated the origin of TAMs in spontaneous pulmonary metastases using the PyMT-ChOVA breast cancer model. Within spontaneous pulmonary metastases of MacBlue x *Cx3cr1*<sup>EGFP/+</sup> x PyMT-ChOVA mice the ECFP<sup>+</sup>/EGFP<sup>+</sup> cells ratio was 0.54±0.14, while EGFP cells were absent in nodule of parabiont mice (**Figure 2E**). These results suggest that TAMs are of dual origins both during the growth of lung carcinoma cells and metastatic cells.

### **Lung interstitial macrophages of embryonic origin accumulate within tumors**

To further confirm that lung interstitial macrophages contributed to the TAM compartment, we performed fate mapping experiments using *Csf1*<sup>MerCreMer</sup>; *Rosa*<sup>LSL-tdTomato</sup> reporter mice pulsed with OH-TAM at E8.5 to label cells derived from erythro-myeloid progenitors (EMP)(Mass et al., 2017; Schulz et al., 2012). In this context, a small fraction of Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac, and to some lesser extent Siglec-F<sup>+</sup> alveolar macrophages were labeled (**Figure 3A**). In the presence of tumor, the embryonic-derived tdTomato<sup>+</sup> Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac strongly expanded but not tdTomato<sup>+</sup> Siglec-F<sup>+</sup> AMs (**Figure 3A, right panel**) confirming the previous observation made in the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> model. Expression of *Tnfrs11a* during early EMP-derived macrophage differentiation allows more efficient and relatively specific lineage tracing of tissue-resident macrophages using the *Tnfrs11a*<sup>Cre</sup> (Mass et al., 2016). Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac and Siglec-F<sup>+</sup> AMs were mostly YFP<sup>+</sup> in the healthy lungs of *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> mice whereas less than 20% of each Mo subsets and neutrophils were labeled consistent with studies showing an embryonic origin of the former populations (Guilliams et al., 2013; Tan and Krasnow, 2016). Upon tumor development, only the proportion of YFP<sup>+</sup> cells among the total Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac diminished in accordance with the appearance of a YFP<sup>-</sup> Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac (**Figure 3B**). YFP<sup>+</sup> Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac, but not Siglec-F<sup>+</sup> AMs, dramatically increased in absolute count confirming the expansion of the embryonic-derived interstitial subset with tumor growth (**Figure 3B, right panel**). These different fate mapping models further confirm that interstitial resident macrophages of embryonic origin contribute to the pool of TAMs in lung tumors together with monocyte-derived macrophages

### Resident and MoD-TAMs harbor distinct phenotypes and distribution

Because of their different origin, we speculated that the distribution and phenotype of EGFP<sup>+</sup>- and ECFP<sup>+</sup>-TAMs might be different. We previously demonstrated that, in tumor-free lungs of MacBlue x *Cx3cr1*<sup>EGFP/+</sup>, EGFP<sup>+</sup> interstitial macrophages were mostly localized in the lung pleura and in the vicinity of large airways (Rodero et al., 2015). Accordingly, in tumor nodules located nearby the lung pleura, EGFP<sup>+</sup> cells showed a gradient of distribution falling with increase distance from the pleura, while the ECFP<sup>+</sup> cell distribution was equal (**Figure 4A**). In tumors that developed in the central alveolar space of the lung, EGFP<sup>+</sup> cells represented 40.5±7.8% of total fluorescent cells while in tumors that developed near large airways, the ratio of EGFP<sup>+</sup> cells was higher (65±8.6%) (**Figure 4B**). EGFP<sup>+</sup> cells displayed a more stellar-like morphology compared to ECFP<sup>+</sup> cells. EGFP<sup>+</sup> cells were relatively sessile but interacted with each other and exhibited a highly protrusive activity across tumor cells (**Figure S3A and video 1 and 2**). The dynamics of ECFP<sup>+</sup> cells was heterogeneous, likely reflecting the diversity of their composition, including monocytes or macrophages with higher displacement compared to EGFP<sup>+</sup> cells as depicted by the relative track straightness distribution (**Figure S3B**).

Similarly to EGFP<sup>+</sup> cells, YFP<sup>+</sup> TAMs in *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> mice were more abundant in tumor nodules developing next to the pleura compared to nodules located in the alveolar space (**Figure 4C**). Along with tumor expansion (between day 15 and 20), accumulation of ECFP<sup>+</sup> cells was observed at the tumor margin, whereas the proportion of EGFP<sup>+</sup> cells remained higher in the tumor core (**Figure S3C**). This suggests that the relative composition of EGFP<sup>+</sup>-TAMs and ECFP<sup>+</sup>-TAMs in the TME is determined by the specific site of tumor development as well as the phase of tumor evolution. Based on phenotypic surface markers (CD206, IA[b], CD11c), we did not find any distinct expression between the two TAM subsets (**Figure S2B**) suggesting that both subsets are composed of M1/M2-like profiles. To further compare the two TAM subsets, we performed whole transcriptome microarray analysis on EGFP<sup>+</sup> and ECFP<sup>+</sup> TAMs sorted 20 days after TC-1 inoculation. Up to 604 differentially

expressed genes (either up or down, with a p-value <0.05 by Student's t-test) were identified between the two TAM subsets (**Figure S3D**). The Ingenuity Knowledge Base identified their association with functional groups and the most relevant groups (with a cut-off value at  $p < 0.01$ , given by the score from Fisher's Exact Test) were listed (**Figure S3E**). These functional groups were involved in cellular signaling, cell morphology and trafficking, tissue remodeling associated to cancer development. We found a set of transcripts related to extracellular matrix and vasculature interactions that were differentially expressed between EGFP<sup>+</sup>-TAMs and ECFP<sup>+</sup>-TAMs. For instance, the transcripts *Marco*, *Mmp8*, *F7*, *Tnfsf14* and *Thbs1* were found to be expressed at higher levels in ECFP<sup>+</sup>-TAMs compared to EGFP<sup>+</sup>-TAMs (**Figure 4D**). The transcripts for *Col14a1*, *Ccl2*, *Cxcl13* as well as *Vcam1* and *Plxna4* (involved in adhesion-dependent processes and angiogenesis, Gambardella et al., 2010; Tamagnone, 2012), were all up-regulated in EGFP<sup>+</sup>-TAMs compared to ECFP<sup>+</sup>-TAMs. *Col14a* *Ccl2*, *Cxcl13* transcripts were also higher in YFP<sup>+</sup> TAMs in the *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> model, whereas YFP<sup>-</sup> TAMs expressed higher level of *Mmp8*. YFP<sup>+</sup> and YFP<sup>-</sup> TAMs expressed similar levels of *csf1r* transcripts (**Figure 4E**). VCAM1 expression was confirmed at the protein level and defined a marker mostly restricted to the EGFP<sup>+</sup>-TAM subset and was expressed accordingly in YFP<sup>+</sup> TAMs of *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> lungs (**Figure 4F**). Near the tumor vasculature, EGFP<sup>+</sup> cells were more abundant than ECFP<sup>+</sup> cells, displaying a typical perivascular-like morphology around the vessels (**Figure 4G**). We concluded that despite a similar surface marker expression profile, ECFP<sup>+</sup>-TAMs and EGFP<sup>+</sup>-TAMs are distinct subsets and we speculated they might be differentially involved in tumor growth.

### **Resident TAMs support tumor cell growth and MoD-cells are associated with tumor spreading in the lung**

The relative contribution of the TAM subsets on tumor growth was next evaluated comparing tumor evolution in WT and CCR2-deficient mice. Tumor growth was similar in WT and *Ccr2*<sup>-/-</sup> mice, as monitored by bioluminescence (**Figure 5A**). However, histological analysis showed

that nodule surface was smaller in CCR2-deficient mice compared to WT mice (**Figure 5B**). This discrepancy might be explained by a more disperse and lower density of tumor cells within pulmonary nodules of WT compared to *Ccr2*<sup>-/-</sup> (**Figure 5C**). Overall, these results confirm that even in the absence of monocyte-derived TAMs, tumor cells can efficiently grow *in vivo* and suggest that resident TAMs are sufficient to support tumor cell expansion while MoD-cells might contribute to tumor cell dissemination.

Transient anti-CSF1R treatment is known to target mature macrophages but does not block monocyte infiltration into tumors (Kitamura et al., 2017). Compared to other resident macrophages, AMs have been described to be uniquely dependent on GM-CSF (Guilliams et al., 2013; Schneider et al., 2014) and as a result should not be targeted by the treatment. Treatment of tumor-bearing WT mice with anti-CSF1R depleted ECFP<sup>+</sup>-TAMs and more profoundly EGFP<sup>+</sup>-TAMs but not monocytes and AMs (**Figure 5D**). Anti-CSF1R treatment does not allow to distinguish the relative contribution of monocytes, ECFP<sup>+</sup>-TAMs and EGFP<sup>+</sup>-TAMs on tumor growth. To investigate the contribution of resident TAMs only on tumor growth, we performed anti-CSF1R treatment on CCR2-deficient mice. This treatment strongly depleted the remaining EGFP<sup>+</sup>-TAMs in tumor nodules of CCR2-deficient mice as well and strongly reduced tumor burden (**Figure 5D-E**). Our results corroborate the role of interstitial lung macrophages as a trophic support for tumor cells while MoD-cells are associated with tumor remodeling and spreading.

### **Distinct sensitivity and recovery of Res-TAMs and MoD-TAMs after chemotherapy**

TAMs play major roles in the response to anti-cancer therapies (Mantovani and Allavena, 2015). We next addressed how the two TAM subsets respond to conventional chemotherapy. Cyclophosphamide (CP) is a classical alkylating agent with known myeloablative properties (Jacquelin et al., 2013). A single injection of CP led to a strong reduction in tumor burden, which relapsed 15 days after chemotherapy (**Figure 6A**). The number of circulating Ly6C<sup>high</sup>-Mo was reduced 2 days after chemotherapy but recovered with a significant overshoot between day 5 and day 10 post-therapy (**Figure S4A**).

Circulating Ly6C<sup>low/-</sup>-Mo displayed a delayed recovery compared to Ly6C<sup>high</sup>-Mo but the numbers of both monocyte subsets finally dropped at day 15 post CP, correlating with tumor relapse (**Figure S4A**). Intravascular CD45 staining was performed and the recovery of myeloid cells in the lungs was monitored (**Figure 6B**). Monocyte and macrophage subsets were also depleted in both vascular and parenchymal compartments of the lungs within 2-3 days (**Figure 6C**). Monocyte subsets transiently rebounded at day 5 after CP treatment and their accumulation was associated with macrophage recovery, peaking at day 10 (**Figure 6C**). Among macrophages, both EGFP<sup>+</sup> and ECFP<sup>+</sup> subsets were depleted by CP treatment but the massive recovery at day 10 was mainly constituted by ECFP<sup>+</sup>-TAMs (**Figure 6D**). ECFP<sup>+</sup> MoD-cells accumulated in the vicinity of living tumor cells between 5 and 10 days post CP and participated in the clearance of the apoptotic debris (**Figure 6E**). The proportion of phagocytic cells among different subsets was quantified by flow cytometry between 10 and 15 days post CP (**Figure 6F**). ECFP<sup>+</sup>-TAMs represented the most abundant phagocytic subsets while EGFP<sup>+</sup>-TAMs poorly contributed to tumor clearance (**Figure 6F**). The numbers of monocytes and macrophages were lower in *Ccr2*<sup>-/-</sup> mice compared to WT mice 15 days after CP treatment (**Figure S4B**). This defect was associated with a reduced efficacy of chemotherapy (**Figure S4C-D**). We conclude that CP treatment targets both EGFP<sup>+</sup>-TAMs and ECFP<sup>+</sup>-TAMs but these subsets differentially recover and contribute to tumor elimination. Because one single dose of CP was not sufficient to completely eradicate the tumor and led to tumor relapse, we next aimed at improving therapy efficacy.

### **Anti-VEGF combination with CP reduces TAM recovery and enhances chemotherapy efficacy**

The pro-angiogenic molecule VEGF has been implicated in vessel reconstruction and tumor relapse following chemotherapy (Hughes et al., 2015; Lewis et al., 2016). In addition, the combination of anti-VEGF with chemotherapy has shown greater efficacy than chemotherapy or targeted therapy alone in patients bearing non-small cell lung cancer and metastatic breast cancer (Cohen et al., 2007; Montero and Gluck, 2012). Because TAMs have been

shown to express VEGFR1 (FLT1) (Qian et al., 2015), we speculated that the combination of anti-VEGF with CP could directly target TAMs and improve therapeutic outcome. Tumor-bearing mice were treated or not with CP in combination or not with anti-VEGF (**Figure 7A**). We determined the impact of the combined therapy on the myeloid signature of the tumor microenvironment using the previous unsupervised viSNE analysis based on 12 parameters including intravascular CD45 staining (dashed gates) (**Figure 1A, S1, and 7B**). The myeloid signature of the vascular compartment was similar in each condition. Anti-VEGF treatment in combination with CP induced a striking reduction of the TAM signature (cluster 1) in comparison to single treatments. Interestingly, in the combined regimen, the tumor-infiltrating Ly6C<sup>high</sup> CD64<sup>+</sup> cell subset (cluster 4) was increased compared to CP or anti-VEGF treatments alone (**Figure 7B**). We thus quantified the recovery of monocytes and macrophages between D5 and D10 after chemotherapy in mice treated with anti-VEGF or isotype control (**Figure 7C**). The combination of CP and anti-VEGF blocked TAM recovery between days 15 and 20, whereas neither the Ly6C<sup>high</sup>-Mo rebound nor the infiltration of Ly6C<sup>high</sup> CD64<sup>+</sup> cells were affected, suggesting that TAM diminution was not a result of a reduction of monocyte infiltration. AM number remained unaffected between the two conditions (**Figure 7C**). The efficacy of the combined therapy was evaluated on advanced stages of tumor development (day 20 after tumor inoculation). Compared to both treatments alone, the combination resulted in prolonged mouse survival and normalization of the lung weight (**Figure 7D**).

### **Anti-VEGF targets Res-TAM and MoD-TAM accumulation**

To further investigate the action of anti-VEGF on myeloid cells, we adoptively transferred bone-marrow monocytes in anti-VEGF or isotype-treated WT mice (**Figure 8A**). The proportion of recovered TAMs was significantly reduced at the expense of Ly6C<sup>high</sup>-Mo (**Figure 8B**) while the infiltration (measured by intravascular CD45 staining) of the latter was unchanged (**Figure 8C**), indicating that anti-VEGF did not block monocyte infiltration but rather reduced their differentiation into TAMs and/or TAM survival. FLT1 expression was

already detected on Ly6C<sup>high</sup> CD64<sup>+</sup> cells, but the expression on Ly6C<sup>high</sup> and Ly6C<sup>low/-</sup>-Mo was low (**Figure S5A**). EGFP<sup>+</sup>-TAMs and ECFP<sup>+</sup>-TAMs harbored similar expression of FLT1 (**Figure 8D**). VEGF was found mainly along blood vessels but also in the tumor parenchyma, in proximity to TAMs without preferential co-localization with ECFP<sup>+</sup> or EGFP<sup>+</sup> cells (**Figure S5B**). Anti-VEGF treatment of tumor-bearing mice led to a significant reduction in the number of TAMs, but the proportions of EGFP<sup>+</sup>-TAMs and ECFP<sup>+</sup>-TAMs were similar demonstrating that both macrophage subsets are reduced by this treatment (**Figure 8E**). Our results support that anti-VEGF targets both monocyte-derived and resident TAM accumulation through a mechanism independent of their recruitment but rather affects their survival or proliferation.

## Discussion

Embryonic-derived macrophages have recently been shown to contribute to the generation of TAMs in the pancreas and in the brain (Bowman et al., 2016; Zhu et al., 2017). These discoveries challenge the dogma on the origin of TAMs and raise the question whether this observation is applicable to other tissues such as the lungs, which are colonized by distinct macrophage subsets. AMs represent the main and typical resident macrophages of the lungs, maintaining immune homeostasis in the alveoli lumen (Trapnell and Whitsett, 2002). AMs acquire their unique signature and self-maintain via GM-CSF-dependent induction of PPAR- $\gamma$  after birth (Guilliams et al., 2013; Schneider et al., 2014). Less is known about the functions and origin of IMs, but it has been suggested that they develop earlier than AMs in the embryo (Tan and Krasnow, 2016) and self-maintain independently of adult hematopoiesis (Gibbings et al., 2017; Rodero et al., 2015).

The implication of the chemokine receptor CCR2 in the recruitment of monocytes and on their subsequent differentiation into TAMs is well established in both primary and metastatic sites of various tumor types. This CCR2/CCL2 axis can contribute to an amplification loop of tumor progression (Franklin et al., 2014; Kitamura et al., 2015; Loyher et al., 2016). In these studies, the role of this axis on resident macrophages could not be excluded. However, lung IMs have been shown to expand independently of CCR2 and to display regulatory functions in the context of allergy (Sabatel et al., 2017).

Using the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> model, we unveiled the accumulation of an EGFP<sup>+</sup> TAM subset that was unaffected by CCR2 deficiency and not reconstituted in parabiosis experiments, demonstrating that this subset originates from macrophages that were already present in the healthy lungs before tumor development. Preferential labeling of CD11b<sup>+</sup> IMs was previously achieved using *Csf1r*<sup>MerCreMer</sup> mice pulsed with OH-TAM at E8.5 (Schulz et al., 2012). Using the same approaches to trace EMP-derived macrophages, we unveiled that embryonically seeded lung-resident IMs persist and proliferate to represent a large fraction of TAMs within pulmonary tumors and confirmed our hypothesis made using the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mouse system. While we could not firmly exclude that some EGFP<sup>+</sup>-TAMs arise



from AMs differentiation, it is unlikely that upon tumor parenchymal infiltration AMs lose the expression of Siglec-F and ECFP reporter while upregulating CD11b and EGFP. No progressive change in the expression of these surface markers that could support this hypothesis was observed in the AM population during tumor development. Thus, resident IMs are likely to represent a unique tissue-resident subset involved in the accumulation of EGFP<sup>+</sup> TAMs. Loss of ECFP expression from monocyte-derived macrophages could lead to overestimation of EGFP<sup>+</sup>-TAMs, however monocyte derived cells maintained ECFP expression in parabiosis and transfer experiment, suggesting that this phenomenon barely occurs during this time frame and would only minimally perturb our quantification of EGFP<sup>+</sup>-TAMs. Fate mapping studies led to similar observations and strengthen the fidelity of the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> system to study lung macrophages. Concomitantly, we observed an increase in the number of Ly6C<sup>high</sup> monocytes. Infiltrating Ly6C<sup>high</sup>-Mo seemed to up-regulate CD64 suggesting an intermediate toward the progressive differentiation into TAMs. We subsequently identified a distinct population of monocyte-derived TAMs arising from CCR2-dependent monocyte recruitment. At later time points, these TAMs became from far the most abundant population. The dual origin of macrophages was also observed in TAMs of LLC lung nodules and PyMT-ChOVA spontaneous pulmonary metastases suggesting that it might occur for any neoplastic tissue development in the lung.

Within lung tumor nodules, the relative distribution and abundance of EGFP<sup>+</sup>-TAMs compared to the recruited ones were in accordance with the localization of IMs prior to tumor development. We previously showed in the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice that interstitial EGFP<sup>+</sup> macrophages are abundant in the pleura, airways and at the periphery of large blood vessels (Rodero et al., 2015). Lineage tracing of yolk sac-derived macrophages labeled mostly IMs that persisted in adults and localized in these same particular locations but scarce in the central lung parenchyma (Tan and Krasnow, 2016). The local environment can dictate macrophage phenotypes *in vivo* (Gosselin et al., 2014; Lavin et al., 2014; van de Laar et al., 2016). Despite a very close proximity between the two TAM subsets in tumor nodules, their transcriptomic profiles were distinct and were associated with different distribution depending

on the anatomic localization of the tumor, further arguing that origin poises macrophages for differing functions. No typical M1 or M2 profile could be attributed to EGFP<sup>+</sup>-TAMs or ECFP<sup>+</sup>-TAMs, suggesting that this paradigm does not fully resolve the polarization process of TAMs. Nevertheless, the relative proportion and specific features of tissue-resident macrophages might contribute to the heterogeneity of different TME according to the anatomical site of tumor development. Further studies are needed to investigate whether it could serve as a prognostic factor of tumor growth and response to therapies.

Anti-CSF1R treatment depleted most of EGFP<sup>+</sup>-TAMs but ECFP<sup>+</sup>-TAMs were only partially targeted while Ly6C<sup>high</sup> monocytes and AMs were unaffected. Despite the lack of ECFP expression in the MacBlue mouse, it was previously shown that adult tissue-macrophages express CSF1R. The differential utilization of the truncated CSF1R promoter of the MacBlue binary transgene in macrophages was proposed to reflect different survival dependency on CSF1. Thus, cell expressing the ECFP reporter would be CSF1-independent in contrast to EGFP<sup>+</sup> macrophages that require the upstream depleted region of the CSF1-regulated promoter region of the MacBlue transgene (Hawley et al., 2018; Sauter et al., 2014). This was supported by the reduced impact of anti-CSF1R treatment on ECFP<sup>+</sup>-TAMs compared to EGFP<sup>+</sup>-TAMs. Depletion of EGFP<sup>+</sup>-TAMs in *Ccr2*<sup>-/-</sup> mice led to drastic reduction in tumor growth, which links resident TAMs more directly to tumor trophic functions. ECFP<sup>+</sup>-TAMs displayed increased motility, in accordance to enriched cellular movement associated pathways and turned up to accumulate at the tumor margin. In this regard, *Mmp8* and *Tnfsf14* enrichment (implicated in airway remodeling) (Doherty et al., 2011) could argue for a licensing of monocyte-derived TAMs for remodeling of the surrounding environment and modification of the tumor architecture. Indeed, recruitment of MoD-cells was associated with reduced tumor cell density, higher spreading and increased invasion of pulmonary nodules. We could not fully differentiate the relative contribution of tumor-infiltrating ECFP<sup>+</sup> monocytes versus ECFP<sup>+</sup>-TAMs. Monocyte-dependent cytotoxic activity could be suspected as observed after CP-induced monocyte rebound. Thus ECFP<sup>+</sup>-cells represent a heterogeneous population balancing between tumor destruction and remodeling, favoring spreading and

invasiveness. This observation raises important questions about cancer therapies targeting TAM subsets and suggests that depleting resident macrophages but keeping the phagocytic activities of MoD-cells would yield a better outcome for chemotherapies.

The targeting of VEGF in combination with chemotherapy including CP (Dellapasqua et al., 2008) has been shown to be beneficial (Motz and Coukos, 2011). Although TAMs have clearly been shown to participate in the process of angiogenesis within tumor (Lewis et al., 2016), few studies have investigated the impact of this therapeutic combination on the immune cellular composition of the TME. Moreover, FLT1 expression and signaling by pulmonary TAMs are implicated in their pro-tumor activity, partly via downstream regulation of the master macrophage regulator CSF1 (Qian et al., 2015). VEGF has been proposed to act as a chemoattractant factor for monocytes (Grunewald et al., 2006; Kaplan et al., 2005) but the beneficial effect of anti-VEGF combination was associated with a drastic reduction of both EGFP<sup>+</sup> resident and ECFP<sup>+</sup> monocyte-derived TAMs without affecting tumor-monocyte infiltration, suggesting that VEGF contributes to monocyte differentiation and/or TAM survival. Indeed, FLT1 expression was increased upon monocyte to macrophage differentiation, which corroborates previous studies (Barleon et al., 1996; Qian et al., 2015). This observation is in accordance with the hypothesis of a loss of anti-tumor activity of tumor-infiltrating monocytes upon differentiation into TAMs. The clinical relevance of our results lies in the fact that anti-VEGF could improve chemotherapy efficacy through functions that go beyond its main expected role on angiogenesis and leukocyte recruitment. Increasing knowledge of the impact of such molecule on the different TAM subsets according to their origin might allow for further development and improvement of anti-cancer dosing regimens and combinations.



### **Author contribution**

PL.L. and P.H. designed, performed the experiments, analyzed and interpreted the data and wrote the manuscript, A.MK., E.G. and B.C. analyzed and interpreted the data, M.L., S.T., C.BC. and Z.D. performed some experiments and wrote the manuscript. N.B. provided reagent and wrote the manuscript, F.G., A.S. and C.C. provided reagent, designed research. A.B. supervised the study, designed, performed the experiments, analyzed and interpreted the data and wrote the manuscript.

### **Acknowledgments**

The authors wish to thank the Plateforme Imagerie Pitié-Salpêtrière (PICPS) for assistance with the two-photon microscope, the animal facility "NAC" for mice breeding assistance and Angéline Duche and Sebastien Jacques from sequencing platform GENOM'IC (Institut Cochin, Paris, France). The authors also thank M. Lambert for the tdTomato viral construct. PL.L. is funded by "Fondation ARC pour la Recherche sur le Cancer" and MSKCC GMTEC's fellowships. P.H. is funded by la "Ligue contre le cancer". This work was supported by funding from the European Community's Seventh Framework Programme (FP7/2007-2013) n°304810 – RAIDs, Inserm, Roche, la "Ligue contre le cancer", FRM "équipe labélisée" and "Fondation ARC pour la recherche sur le cancer" (to A.B.) and NIH NCI (P30CA008748) MSKCC core grant, NIH/NIAID 1R01AI130345-01 and NIH/NHLBI 1 R01HL138090-01 (to F.G.). Ariel Savina is employed by Roche. The authors declare no further conflicts of interest.

## References

- Amir el, A.D., K.L. Davis, M.D. Tadmor, E.F. Simonds, J.H. Levine, S.C. Bendall, D.K. Shenfeld, S. Krishnaswamy, G.P. Nolan, and D. Pe'er. 2013. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol* 31:545-552.
- Barleon, B., S. Sozzani, D. Zhou, H.A. Weich, A. Mantovani, and D. Marme. 1996. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* 87:3336-3343.
- Boissonnas, A., F. Licata, L. Poupel, S. Jacquelin, L. Fetler, S. Krumeich, C. Thery, S. Amigorena, and C. Combadiere. 2013. CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. *Neoplasia* 15:85-94.
- Bowman, R.L., F. Klemm, L. Akkari, S.M. Pyonteck, L. Sevenich, D.F. Quail, S. Dhara, K. Simpson, E.E. Gardner, C.A. Iacobuzio-Donahue, C.W. Brennan, V. Tabar, P.H. Gutin, and J.A. Joyce. 2016. Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. *Cell Rep* 17:2445-2459.
- Broz, M.L., M. Binnewies, B. Boldajipour, A.E. Nelson, J.L. Pollack, D.J. Erle, A. Barczak, M.D. Rosenblum, A. Daud, D.L. Barber, S. Amigorena, L.J. Van't Veer, A.I. Sperling, D.M. Wolf, and M.F. Krummel. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell* 26:638-652.
- Chen, T.J., and N. Kotecha. 2014. Cytobank: providing an analytics platform for community cytometry data analysis and collaboration. *Curr Top Microbiol Immunol* 377:127-157.
- Cohen, M.H., J. Gootenberg, P. Keegan, and R. Pazdur. 2007. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. *Oncologist* 12:713-718.
- Cortez-Retamozo, V., M. Etzrodt, A. Newton, P.J. Rauch, A. Chudnovskiy, C. Berger, R.J. Ryan, Y. Iwamoto, B. Marinelli, R. Gorbato, R. Forghani, T.I. Novobrantseva, V. Koteliensky, J.L. Figueiredo, J.W. Chen, D.G. Anderson, M. Nahrendorf, F.K. Swirski, R. Weissleder, and M.J. Pittet. 2012. Origins of tumor-associated macrophages and neutrophils. *Proc Natl Acad Sci U S A* 109:2491-2496.
- De Palma, M., and C.E. Lewis. 2013. Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell* 23:277-286.
- Dellapasqua, S., F. Bertolini, V. Bagnardi, E. Campagnoli, E. Scarano, R. Torrisi, Y. Shaked, P. Mancuso, A. Goldhirsch, A. Rocca, E. Pietri, and M. Colleoni. 2008. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. *J Clin Oncol* 26:4899-4905.
- Doherty, T.A., P. Soroosh, N. Khorram, S. Fukuyama, P. Rosenthal, J.Y. Cho, P.S. Norris, H. Choi, S. Scheu, K. Pfeffer, B.L. Zuraw, C.F. Ware, D.H. Broide, and M. Croft. 2011. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. *Nat Med* 17:596-603.
- Engelhardt, J.J., B. Boldajipour, P. Beemiller, P. Pandurangi, C. Sorensen, Z. Werb, M. Egeblad, and M.F. Krummel. 2012. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. *Cancer Cell* 21:402-417.
- Franklin, R.A., W. Liao, A. Sarkar, M.V. Kim, M.R. Bivona, K. Liu, E.G. Pamer, and M.O. Li. 2014. The cellular and molecular origin of tumor-associated macrophages. *Science* 344:921-925.
- Gambardella, L., M. Hemberger, B. Hughes, E. Zudaire, S. Andrews, and S. Vermeren. 2010. PI3K signaling through the dual GTPase-activating protein ARAP3 is essential for developmental angiogenesis. *Sci Signal* 3:ra76.
- Gibbins, S.L., S.M. Thomas, S.M. Atif, A.L. McCubrey, A.N. Desch, T. Danhorn, S.M. Leach, D.L. Bratton, P.M. Henson, W.J. Janssen, and C.V. Jakubzick. 2017. Three Unique Interstitial Macrophages in the Murine Lung at Steady State. *Am J Respir Cell Mol Biol* 57:66-76.

- Gomez Perdiguero, E., K. Klapproth, C. Schulz, K. Busch, E. Azzoni, L. Crozet, H. Garner, C. Trouillet, M.F. de Bruijn, F. Geissmann, and H.R. Rodewald. 2015. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature* 518:547-551.
- Gosselin, D., V.M. Link, C.E. Romanoski, G.J. Fonseca, D.Z. Eichenfield, N.J. Spann, J.D. Stender, H.B. Chun, H. Garner, F. Geissmann, and C.K. Glass. 2014. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell* 159:1327-1340.
- Grunewald, M., I. Avraham, Y. Dor, E. Bachar-Lustig, A. Itin, S. Jung, S. Chimenti, L. Landsman, R. Abramovitch, and E. Keshet. 2006. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. *Cell* 124:175-189.
- Guilliams, M., I. De Kleer, S. Henri, S. Post, L. Vanhoutte, S. De Prijck, K. Deswarte, B. Malissen, H. Hammad, and B.N. Lambrecht. 2013. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med* 210:1977-1992.
- Hamon, P., P.L. Loyher, C. Baudesson de Chanville, F. Licata, C. Combadiere, and A. Boissonnas. 2016. CX3CR1-dependent endothelial margination modulates Ly6Chigh monocyte systemic deployment upon inflammation in mice. *Blood*
- Hawley, C.A., R. Rojo, A. Raper, K.A. Sauter, Z.M. Lisowski, K. Grabert, C.C. Bain, G.M. Davis, P.A. Louwe, M.C. Ostrowski, D.A. Hume, C. Pridans, and S.J. Jenkins. 2018. Csf1r-mApple Transgene Expression and Ligand Binding In Vivo Reveal Dynamics of CSF1R Expression within the Mononuclear Phagocyte System. *J Immunol*
- Hughes, R., B.Z. Qian, C. Rowan, M. Muthana, I. Keklikoglou, O.C. Olson, S. Tazzyman, S. Danson, C. Addison, M. Clemons, A.M. Gonzalez-Angulo, J.A. Joyce, M. De Palma, J.W. Pollard, and C.E. Lewis. 2015. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. *Cancer Res* 75:3479-3491.
- Jacquelin, S., F. Licata, K. Dorgham, P. Hermand, L. Poupel, E. Guyon, P. Deterre, D.A. Hume, C. Combadiere, and A. Boissonnas. 2013. CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice. *Blood* 122:674-683.
- Ji, H., E.Y. Chang, K.Y. Lin, R.J. Kurman, D.M. Pardoll, and T.C. Wu. 1998. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. *Int J Cancer* 78:41-45.
- Jung, S., J. Aliberti, P. Graemmel, M.J. Sunshine, G.W. Kreutzberg, A. Sher, and D.R. Littman. 2000. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol Cell Biol* 20:4106-4114.
- Kaplan, R.N., R.D. Riba, S. Zacharoulis, A.H. Bramley, L. Vincent, C. Costa, D.D. MacDonald, D.K. Jin, K. Shido, S.A. Kerns, Z. Zhu, D. Hicklin, Y. Wu, J.L. Port, N. Altorki, E.R. Port, D. Ruggero, S.V. Shmelkov, K.K. Jensen, S. Rafii, and D. Lyden. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 438:820-827.
- Kitamura, T., D. Doughty-Shenton, L. Cassetta, S. Fraggogianni, D. Brownlie, Y. Kato, N. Carragher, and J.W. Pollard. 2017. Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer. *Front Immunol* 8:2004.
- Kitamura, T., B.Z. Qian, D. Soong, L. Cassetta, R. Noy, G. Sugano, Y. Kato, J. Li, and J.W. Pollard. 2015. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. *J Exp Med* 212:1043-1059.
- Lavin, Y., D. Winter, R. Blecher-Gonen, E. David, H. Keren-Shaul, M. Merad, S. Jung, and I. Amit. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* 159:1312-1326.
- Lewis, C.E., A.S. Harney, and J.W. Pollard. 2016. The Multifaceted Role of Perivascular Macrophages in Tumors. *Cancer Cell* 30:365.
- Lin, K.Y., F.G. Guarnieri, K.F. Staveley-O'Carroll, H.I. Levitsky, J.T. August, D.M. Pardoll, and T.C. Wu. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. *Cancer Res* 56:21-26.

- Loyher, P.L., J. Rochefort, C. Baudesson de Chanville, P. Hamon, G. Lescaille, C. Bertolus, M. Guillot-Delost, M.F. Krummel, F.M. Lemoine, C. Combadiere, and A. Boissonnas. 2016. CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity. *Cancer Res* 76:6483-6494.
- Maeda, K., Y. Kobayashi, N. Udagawa, S. Uehara, A. Ishihara, T. Mizoguchi, Y. Kikuchi, I. Takada, S. Kato, S. Kani, M. Nishita, K. Marumo, T.J. Martin, Y. Minami, and N. Takahashi. 2012. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. *Nat Med* 18:405-412.
- Mantovani, A., and P. Allavena. 2015. The interaction of anticancer therapies with tumor-associated macrophages. *J Exp Med* 212:435-445.
- Mass, E., I. Ballesteros, M. Farlik, F. Halbritter, P. Gunther, L. Crozet, C.E. Jacome-Galarza, K. Handler, J. Klughammer, Y. Kobayashi, E. Gomez-Perdiguero, J.L. Schultze, M. Beyer, C. Bock, and F. Geissmann. 2016. Specification of tissue-resident macrophages during organogenesis. *Science* 353:
- Mass, E., C.E. Jacome-Galarza, T. Blank, T. Lazarov, B.H. Durham, N. Ozkaya, A. Pastore, M. Schwabenland, Y.R. Chung, M.K. Rosenblum, M. Prinz, O. Abdel-Wahab, and F. Geissmann. 2017. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. *Nature* 549:389-393.
- Misharin, A.V., L. Morales-Nebreda, G.M. Mutlu, G.R. Budinger, and H. Perlman. 2013. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. *Am J Respir Cell Mol Biol* 49:503-510.
- Montero, A., and S. Gluck. 2012. Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. *Case Rep Oncol* 5:687-692.
- Motz, G.T., and G. Coukos. 2011. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. *Nat Rev Immunol* 11:702-711.
- Ovchinnikov, D.A., W.J. van Zuylen, C.E. DeBats, K.A. Alexander, S. Kellie, and D.A. Hume. 2008. Expression of Gal4-dependent transgenes in cells of the mononuclear phagocyte system labeled with enhanced cyan fluorescent protein using Csflr-Gal4VP16/UAS-ECFP double-transgenic mice. *J Leukoc Biol* 83:430-433.
- Pollard, J.W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. *Nat Rev Cancer* 4:71-78.
- Qian, B.Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L.R. Campion, E.A. Kaiser, L.A. Snyder, and J.W. Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. *Nature* 475:222-225.
- Qian, B.Z., and J.W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. *Cell* 141:39-51.
- Qian, B.Z., H. Zhang, J. Li, T. He, E.J. Yeo, D.Y. Soong, N.O. Carragher, A. Munro, A. Chang, A.R. Bresnick, R.A. Lang, and J.W. Pollard. 2015. FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. *J Exp Med* 212:1433-1448.
- Rodero, M.P., L. Poupel, P.L. Loyher, P. Hamon, F. Licata, C. Pessel, D.A. Hume, C. Combadiere, and A. Boissonnas. 2015. Immune surveillance of the lung by migrating tissue monocytes. *Elife* 4:e07847.
- Sabatel, C., C. Radermecker, L. Fievez, G. Paulissen, S. Chakarov, C. Fernandes, S. Olivier, M. Toussaint, D. Pirotin, X. Xiao, P. Quatresooz, J.C. Sirard, D. Cataldo, L. Gillet, H. Bouabe, C.J. Desmet, F. Ginhoux, T. Marichal, and F. Bureau. 2017. Exposure to Bacterial CpG DNA Protects from Airway Allergic Inflammation by Expanding Regulatory Lung Interstitial Macrophages. *Immunity* 46:457-473.
- Saeed, A.I., N.K. Bhagabati, J.C. Braisted, W. Liang, V. Sharov, E.A. Howe, J. Li, M. Thiagarajan, J.A. White, and J. Quackenbush. 2006. TM4 microarray software suite. *Methods Enzymol* 411:134-193.



- Saeed, A.I., V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa, T. Currier, M. Thiagarajan, A. Sturn, M. Snuffin, A. Rezantsev, D. Popov, A. Ryltsov, E. Kostukovich, I. Borisovsky, Z. Liu, A. Vinsavich, V. Trush, and J. Quackenbush. 2003. TM4: a free, open-source system for microarray data management and analysis. *Biotechniques* 34:374-378.
- Sauter, K.A., C. Pridans, A. Sehgal, C.C. Bain, C. Scott, L. Moffat, R. Rojo, B.M. Stutchfield, C.L. Davies, D.S. Donaldson, K. Renault, B.W. McColl, A.M. Mowat, A. Serrels, M.C. Frame, N.A. Mabbott, and D.A. Hume. 2014. The MacBlue binary transgene (csf1r-gal4VP16/UAS-ECFP) provides a novel marker for visualisation of subsets of monocytes, macrophages and dendritic cells and responsiveness to CSF1 administration. *PLoS One* 9:e105429.
- Schneider, C., S.P. Nobs, M. Kurrer, H. Rehrauer, C. Thiele, and M. Kopf. 2014. Induction of the nuclear receptor PPAR-gamma by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. *Nat Immunol* 15:1026-1037.
- Schulz, C., E. Gomez Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf, M. Prinz, B. Wu, S.E. Jacobsen, J.W. Pollard, J. Frampton, K.J. Liu, and F. Geissmann. 2012. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science* 336:86-90.
- Tamagnone, L. 2012. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. *Cancer Cell* 22:145-152.
- Tan, S.Y., and M.A. Krasnow. 2016. Developmental origin of lung macrophage diversity. *Development* 143:1318-1327.
- Trapnell, B.C., and J.A. Whitsett. 2002. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. *Annu Rev Physiol* 64:775-802.
- van de Laar, L., W. Saelens, S. De Prijck, L. Martens, C.L. Scott, G. Van Isterdael, E. Hoffmann, R. Beyaert, Y. Saeys, B.N. Lambrecht, and M. Guillems. 2016. Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages. *Immunity* 44:755-768.
- Wyckoff, J.B., Y. Wang, E.Y. Lin, J.F. Li, S. Goswami, E.R. Stanley, J.E. Segall, J.W. Pollard, and J. Condeelis. 2007. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. *Cancer Res* 67:2649-2656.
- Zhu, Y., J.M. Herndon, D.K. Sojka, K.W. Kim, B.L. Knolhoff, C. Zuo, D.R. Cullinan, J. Luo, A.R. Bearden, K.J. Lavine, W.M. Yokoyama, W.G. Hawkins, R.C. Fields, G.J. Randolph, and D.G. DeNardo. 2017. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. *Immunity* 47:597.

## Figure Legends

### Figure 1: Lung macrophage subsets differentially accumulate during tumor development

**(A)** Representative tSNE dimension 1 and 2 plots of the lung myeloid compartment evolution after TC-1 cell intravenous inoculation. Upper panel delineates cell blood/tissue partitioning (dashed gates). Color clusters are represented over time (Lower panels). **(B)** Blood/tissue partitioning monitoring of lung monocytes and macrophages during tumor growth. Bars represent mean of the absolute number $\pm$ SEM/mg of tissue (Upper panels), or absolute number per whole lung (Lower panels). Statistical differences are indicated compared to D0. For all panels n=6-8 mice per time point out of 3 independent experiments, Two-way ANOVA was performed. \*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001; \*\*\*\*: p<0.0001). See also Figures S1 and S2.

### Figure 2: Macrophages have distinct origins within lung tumors

**(A)** Lung cryo-sections of tumor free and TC-1<sup>tdTomato</sup> tumor bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice show the distribution of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells within tumor nodules over time. Scale bar 50 $\mu$ m. **(B)** (Left panel) Dot plots show the relative proportion of macrophage subsets in tumor-free, tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> (WT) and MacBlue x *Cx3cr1*<sup>EGFP/+</sup> x *Ccr2*<sup>-/-</sup> (*Ccr2*<sup>-/-</sup>) mice at indicated time points, numbers indicate the mean percentage $\pm$ SD of ECFP<sup>+</sup>EGFP<sup>+</sup> TAMs (Right panel). Whiskers graph shows the absolute number per mg of tissue of indicated myeloid subsets in WT and *Ccr2*<sup>-/-</sup> mice (n=10 mice out of 3 independent experiments, Two-way ANOVA with Bonferroni multiple comparisons test was performed). **(C)** (Left panels) Lung cryo-sections show the distribution of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells in TC-1 tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> (WT), MacBlue x *Cx3cr1*<sup>EGFP/+</sup> x *Ccr2*<sup>-/-</sup> (*Ccr2*<sup>-/-</sup>) mice and C57Bl6 host parabiont with MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice, scale bars 100 $\mu$ m. (Right panel) ratio of ECFP<sup>+</sup>/EGFP<sup>+</sup> cell numbers in lung tumors. Each dot represents mean of ECFP<sup>+</sup>/EGFP<sup>+</sup> cell ratio from different tumor nodules per mouse, red bars indicate mean,

mice are pooled from at least 2 independent experiments. **(D)** (Left panel) Lung cryo-sections show the distribution of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells in LLC tumor bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mouse (D15), scale bar 50μm, and (Middle panel) ratio of ECFP<sup>+</sup>/EGFP<sup>+</sup> cells in LLC tumors. Each dot represents mean of ECFP<sup>+</sup>/EGFP<sup>+</sup> cell ratio from different tumor nodules per mouse, red bar indicates mean, mice are pooled from 2 independent experiments. **(E)** Lung cryo-section shows the distribution of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells in spontaneous pulmonary metastases from MacBlue x *Cx3cr1*<sup>EGFP/+</sup> x PyMT-ChOVA mouse, scale bar 50μm (Left panel). Middle panel shows the lack of EGFP<sup>+</sup> cells in pulmonary metastases from C57Bl6 PyMT-ChOVA host parabiont. Right panel shows the quantification based on histological analyses. Each dot represents mean of ECFP<sup>+</sup> /EGFP<sup>+</sup> cell ratio from different tumor nodules per mouse, red bar indicates mean, all mice are independents. ANOVA with Bonferroni multiple comparisons test were performed. For all panels \*: p<0.05; \*\*\*: p<0.001; \*\*\*\*: p<0.0001.

### **Figure 3: Lung interstitial macrophages are of embryonic origin and accumulate within tumors**

**(A)** (Left panels) Dot plots show tdTomato<sup>+</sup> myeloid cell subsets in *Csf1r*<sup>MeriCreMer</sup>; *Rosa*<sup>LSL-tdTomato</sup> after OH-TAM pulse at E8.5 in adult tumor-free mice and 15 days after TC-1 inoculation. Mean percentage±SD of tdTomato<sup>+</sup> cells among each subset is indicated. Right panel shows the numbers per mg of tissue of the tdTomato<sup>+</sup> AMs and Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac. Bars represent mean of 4 mice per group out of 2 independent experiments. Two-way ANOVA with Bonferroni multiple comparisons test was performed. **(B)** (Left panels) Dot plots show YFP<sup>+</sup> myeloid cell subsets of IMs in *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> mice. Mean percentage±SD of YFP<sup>+</sup> cells among each subset is indicated. Right panel shows the absolute number per mg of YFP<sup>+</sup> AMs and Ly6C<sup>low/-</sup> CD64<sup>+</sup> Mac. Bars represent mean of 4 mice per group out of 2 independent experiments. Two-way ANOVA with Bonferroni multiple comparisons test was performed. For all panels \*: p<0.05; \*\*\*: p <0.001.

**Figure 4: Resident and MoD-TAMs harbor distinct phenotypes and anatomic distribution**

**(A)** Lung cryo-section shows the distribution of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells in TC-1 pulmonary tumor nodule located in the vicinity of the pleura. Graph represents the relative distribution of EGFP<sup>+</sup> cells and ECFP<sup>+</sup> MoD-cells as a function of the distance from the surface (pleura) (Bars represent means $\pm$ SD of 4 mice out of 2 independent experiments; Two-way ANOVA was performed), scale bar 50 $\mu$ m. **(B)** Lung cryo-sections show the distribution of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells in pulmonary tumor nodules located in the alveolar space or near large airways, 15 days after TC-1 inoculation, scale bars 50 $\mu$ m. Graph represents the percentage of EGFP<sup>+</sup> cells among fluorescent cells in each sub-anatomic compartment (Dots represent the mean ratio per mouse, mice are pooled from 2 independent experiments and red bars indicate mean. Unpaired Student's t-test was performed). **(C)** Lung cryo-sections of *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> mice shows YFP<sup>+</sup> cells in pulmonary tumor nodules located in the pleura or in the alveolar space 15 days after tdTomato<sup>+</sup> TC-1 inoculation, scale bars 15 $\mu$ m. Graph represents the number of YFP<sup>+</sup> cells in each sub-anatomic compartment (Dots represent the mean ratio per mouse, mice are pooled from 2 independent experiments and bars indicate means, One-way ANOVA was performed). **(D)** Heatmap shows a selection of transcripts involved in extracellular matrix interaction and remodeling, differentially expressed between EGFP<sup>+</sup> and ECFP<sup>+</sup>-TAMs. **(E)** Expression of indicated genes, relative to GAPDH (2<sup>- $\Delta$ Ct</sup>), as determined by qPCR of FACS sorted YFP<sup>+</sup> and YFP<sup>-</sup> TAMs in *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> mice. Each dot represents one mouse, pooled from 2 independent experiments **(F)** (Left panel) Representative histogram shows VCAM expression gated on TAM subsets from MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice. Middle panel shows the quantification of VCAM1 expression by EGFP<sup>+</sup> and ECFP<sup>+</sup>-TAMs in MacBlue x *Cx3cr1*<sup>EGFP/+</sup>. Right panel represents the quantification of VCAM1 expression by YFP<sup>+</sup> and YFP<sup>-</sup> macrophages in *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> mice. Mice are pooled from 3 independent experiments, bars indicate means, unpaired Student's t-test was performed. **(G)** (Left panel) TPLSM 3D reconstruction shows

the perivascular location of the EGFP<sup>+</sup> cell network within a tumor nodule, scale bar 10µm. (Middle panel) Lung cryo-section from TC-1 tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> at day 15 shows fluorescent subset distribution regarding tumor vasculature using CD31 staining. Close interactions of EGFP<sup>+</sup> cells with the vasculature are indicated (white arrows), scale bar 50µm. (Right panel) Scatter plot represents the relative proportion of perivascular EGFP<sup>+</sup> cells and ECFP<sup>+</sup> cells in tumor nodules (Dots represent the mean proportion per mouse pooled from at least 2 independent experiments; bars indicate means unpaired Student's t-test was performed). For all panels \*: p<0.05; \*\*: p<0.01; \*\*\*: p <0.001; \*\*\*\*: p<0.0001 See also Figure S3 and video 1-2.

**Figure 5: Res-macrophages support tumor cell growth and MoD-cells are associated with tumor spreading in the lung**

**(A)** Tumor growth was monitored in WT and *Ccr2*<sup>-/-</sup> mice by bioluminescence imaging (graphs represent mean±SEM of n=10 mice per group from 2 independent experiments). **(B)** (Left panels) Wide field images of a whole lung cryo-section 15 days after TC-1 inoculation in WT and *Ccr2*<sup>-/-</sup> mice. White mask indicates nodule size and distribution, scale bars 1mm. (Right panel) Graph shows the relative distribution of nodule areas (n=5-7 mice in each group out of 3 independent experiments, Two-way ANOVA comparing WT and *Ccr2*<sup>-/-</sup> frequency of each distribution was performed). **(C)** (Left panels) TPLSM 3D reconstructions show tumor cell density in a representative nodule from TC-1<sup>tdTomato</sup> tumor-bearing WT and *Ccr2*<sup>-/-</sup> mice, white arrows indicate spread tumor cells, scale bars 30µm. (Right panel) Tumor cell density was measured using 3D-reconstruction images of tdTomato<sup>+</sup> tumor nodule. Dots represent the mean of at least 4 different tumor nodules per mouse, pooled from 2 independent experiments, bars indicate means, unpaired Student's t-test was performed). **(D)** Boxes and whiskers graph represents numbers per mg of lung of each indicated myeloid subset after indicated treatment at day 15; Tumor-bearing WT and *Ccr2*<sup>-/-</sup> mice were treated every two days with anti-CSF1R between D5 and D14 (n=6 mice from 2 independent experiments. One-way ANOVA comparing each subset individually for each condition was

performed). **(E)** (Left panels) Lung cryo-sections of TC-1<sup>tdTomato</sup> tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> x *Ccr2*<sup>-/-</sup> mice treated with anti-CSF1R or isotype control show depletion of EGFP<sup>+</sup> cells at D15, scale bars 50µm. (Right panel) Tumor burden was monitored by bioluminescence imaging after TC-1-Luc inoculation. Mice were treated every two days with anti-CSF1R starting D5 (Graphs represent mean±SEM, n= 10 mice per group out of 2 independent experiments. Two-way ANOVA with Bonferoni multiple comparisons test was performed). For all panels \*: p<0.05; \*\*: p<0.01; \*\*\*: p <0.001; \*\*\*\*: p<0.0001.

**Figure 6: Distinct sensitivity and recovery of Res-TAMs and MoD-TAMs after chemotherapy**

**(A)** Impact of CP treatment on tumor growth was monitored by bioluminescence imaging (Graphs represent mean±SEM of n=10 mice per group out of 3 independent experiments). **(B)** Dot plots show Ly6C and CD64 expressions of Siglec-F<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>-</sup> lung cells over time after CP treatment. Mean percentage±SD of cells in each quadrant are indicated. **(C)** Blood/tissue partitioning monitoring of lung monocytes and macrophages during tumor growth post chemotherapy (Graphs represent mean of the absolute number±SEM/mg of tissue, n=6-10 mice per time point out of 2-4 independent experiments, Two-way ANOVA with Bonferroni multiple comparisons test was performed. Only statistical differences compared to day of treatment (day 0) are indicated for each compartment). **(D)** Box and Whiskers graph shows the absolute number per mg of tissue of ECFP<sup>+</sup>-TAMs and EGFP<sup>+</sup>-TAMs from MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice after CP (n= 4-10 mice per time point out of 3 independent experiments, Two-way ANOVA with Bonferroni multiple comparisons test was performed). **(E)** Lung cryo-sections of TC-1<sup>tdTomato</sup> tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mice show TAM subset distribution within tumor nodules following CP treatment, scale bars 50µm. **(F)** (Left panels) Dot plots show TC-1<sup>tdTomato</sup> phagocytosis by the indicated mononuclear phagocyte subsets (red). Fluorescent background from non-fluorescent TC-1 tumor is overlaid (black). (Right panels) Boxes and whiskers graphs show the relative proportion of phagocytic cells among indicated subsets at 10 and 15 days after CP treatment

(n= 9 mice out of 3 independent experiments). For all panels \*:  $p<0.05$ ; \*\*:  $p<0.01$ ; \*\*\*:  $p<0.001$ ; \*\*\*\*:  $p<0.0001$ . See also Figure S4.

**Figure 7: Anti-VEGF combination with CP reduces TAM recovery and enhances chemotherapy efficacy**

**(A)** Tumor bearing mice were treated with CP 10 days after tumor inoculation and treated or not every two days with anti-VEGF. **(B)** Representative tSNE dimension 1 and 2 plots show the impact of the different therapies on the myeloid signature at D15. Cell subsets are color grouped and dashed black gates delineate blood/tissue partitioning. **(C)** Blood/tissue partitioning monitoring of lung monocytes and macrophages during tumor growth at days 15 and 20 after CP or CP+anti-VEGF (Bars represent mean of the total number of cell $\pm$ SEM. For all panels n=6 mice per time point out of 2 independent experiments, Two-way ANOVA with Bonferroni multiple comparisons test was performed). **(D)** Survival curve shows the efficacy of combined therapy started from day 20 (n=7 mice per group, data are representative of 2 experiments, Log-rank (Mantel-cox) test was performed to compare each survival curve with the one of CP+anti-VEGF). Corresponding lung weights are reported (one-way ANOVA with Bonferroni multiple comparisons test was performed). For all panels \*:  $p<0.05$ ; \*\*:  $p<0.01$ ; \*\*\*:  $p<0.001$ .

**Figure 8: Anti-VEGF targets Res-TAM and MoD-TAM accumulation**

**(A)** (Upper panel) Bone marrow monocytes from MacBlue mice were adoptively transferred in tumor-bearing WT mice treated or not with anti-VEGF. (Lower panels) Representative overlay dot plots show the phenotype of recovered MoD-cells from tumor-bearing mice treated (green) or not with anti-VEGF (black) 24h after transfer. **(B)** Graph shows the relative proportion of recovered cells in each mouse pooled from two independent experiments (Black bars indicate means, Two-way ANOVA with Bonferroni multiple comparisons test was performed). **(C)** Graph shows the proportion of Ly6C<sup>high</sup>-Mo infiltration evaluated by blood/tissue partitioning in each mouse pooled from 2 independent experiments (Black bars indicate means, Student's t-test was performed). **(D)** Representative histogram plot of FTL1

expression by ECFP<sup>+</sup> and ECFP<sup>+</sup>-TAMs, mean percentage $\pm$ SD of FLT1<sup>+</sup> cell in each subset out of 6 mice from 2 independent experiments are indicated. **(E)** Left panel shows the number of TAMs/mg in indicated conditions. Right panel shows the relative proportion of TAMs in mice treated with anti-VEGF or isotype. Black bars indicate means of 2 independent experiments, Student's t-test was performed. For all panels ns = non-significant; \*: p<0.05; \*\*\*\*: p<0.0001.



## Materials and Methods

### Mice and fate mapping

C57Bl6 mice were purchased from JANVIER LABS (Le Genest, Saint Isle, France). *Cx3cr1*<sup>EGFP/+</sup> (Jung et al., 2000), *Csf1r*-Gal4VP16/UAS-ECFP (MacBlue)(Ovchinnikov et al., 2008), and *Ccr2*<sup>-/-</sup> mice were intercrossed to generate MacBlue × *Cx3cr1*<sup>EGFP/+</sup>, MacBlue × *Cx3cr1*<sup>EGFP/+</sup> × *Ccr2*<sup>-/-</sup> littermate mouse strains. These strains, and MMTV PyMT-P2A-mCherry-P2A-OVA (PyMT-ChOVA) mice (Engelhardt et al., 2012) were bred at Pitié-Salpêtrière animal facility. *Csf1r*<sup>MeriCreMer</sup>; *Rosa26*<sup>tdTomato-LSL</sup> (Qian et al., 2011) and *Tnfrs11a*<sup>Cre</sup>; *Rosa26*<sup>YFP-LSL</sup> (Maeda et al., 2012) were bred at the Memorial Sloan-Kettering Research Animal Resource Center. For the labeling of the EMP lineage, pulse labeling was performed in *Csf1r*<sup>MeriCreMer</sup>; *Rosa26*<sup>tdTomato-LSL</sup> E8.5 embryos with 4-hydroxytamoxifen (4-OHT, Sigma-Aldrich). Embryonic development was estimated considering the day of vaginal plug formation as 0.5 days post-coitum. Cre recombination was induced by a single injection of 37.5 mg per kg (body weight) of 4-OHT into pregnant females. 4-OHT was supplemented with 18.75 mg per kg (body weight) progesterone (Sigma-Aldrich) to counteract the mixed estrogen agonist effects of tamoxifen, which can result in fetal abortions.

All mice were maintained under SPF conditions and used between 8 and 14 weeks old except for PyMT-ChOVA that develop primary breast tumors and lung metastases at around 25 weeks.

### Ethical statement

All experiment protocols were approved by the French animal experimentation and ethics committee and validated by “Service Protection et Santé Animales, Environnement” with the number A-75-2065 for tumor experiments and A-75-1315 for parabiosis experiments. Sample sizes were chosen to assure reproducibility of the experiments and according to the 3Rs of animal ethic regulation. Animal procedures involving *Csf1r*<sup>MeriCreMer</sup>; *Rosa26*<sup>tdTomato-LSL</sup> and

*Tnfrs11a<sup>Cre</sup>*; *Rosa26<sup>YFP-LSL</sup>* were performed in adherence to project license IACUC 15-04-006, issued by Institution Review Board from MSKCC.

## **Parabiosis**

C57Bl6 female host parabionts were generated with MacBlue x *Cx3cr1<sup>EGFP/+</sup>* females. Blood T cell chimerism was tested after 2 weeks and was between 40-60% whereas Ly6C<sup>high</sup>-Mo chimerism was 10-20%. At this time, both animals were injected with TC-1 cells and analyzed 15 days later.

## **Cells**

The TC-1 tumor cell line was derived from primary lung epithelial cells of a C57Bl6 mouse co-transformed with HPV-16 oncoproteins E6 and E7 and c-Ha-ras oncogene (Ji et al., 1998; Lin et al., 1996). TC-1 cells expressing Luciferase (TC-1-Luc) were kindly provided by Pr. Wu (Johns Hopkins University). TC-1<sup>tdTomato</sup> cell line was generated by infection of TC-1 cells with a tdTomato-lentivirus (kindly provided by M. Lambert, Institut Cochin, Paris, France). Cells were expanded and sorted with BD FACS AriaIII (platform CyBio, Institut Cochin, Paris, France). TC-1<sup>tdTomato</sup> cells were >97% pure. Lewis lung carcinoma (CRL-1642) were obtained from ATCC. All cell lines were cultured in Roswell Park Memorial Institute (RPMI)-1640 with 10% fetal bovine serum, Na-Pyruvate, anti-biotic and anti-mitotic (Gibco, Invitrogen, Cergy Pontoise, France) and incubated at 37°C in 5% CO<sub>2</sub>. For *in vivo* experiments, 5x10<sup>5</sup> cells were injected intravenously in the tail vein to generate lung tumors.

## **Blood/tissue partitioning**

Intravascular CD45 labeling was performed as previously described (Hamon et al., 2016; Rodero et al., 2015). Mice were injected intravenously with 1µg of anti-CD45 (clone 30-F11). Two minutes after injection blood was drawn and mice were sacrificed. Lungs were harvested and bathed in a large volume of PBS.

## **Anti-cancer therapies**

Cyclophosphamide (Sigma-Aldrich, Saint-Quentin Fallavier, France) treatment was performed by a single intraperitoneal injection diluted in phosphate-buffered saline (PBS) at 175mg/kg at 10 days after tumor inoculation or at 20 days for advanced cancer treatment protocols. The anti-VEGF antibody (B20-4.1.1) and isotype control were supplied by Genentech, San Francisco, CA, USA. Antibodies were administrated intraperitoneally at 5mg/kg, every two days after chemotherapy. The anti-CSF1R antibody (AFS98, BioXcell, Lebanon, NH, USA) or Rat IgG2a  $\kappa$  isotype controls were administrated intraperitoneally at 50 mg/kg every two days starting D5.

## **Flow Cytometry**

Blood was drawn via retro-orbital puncture with heparin and directly stained with antibodies. After staining, erythrocytes were lysed with buffer containing 0.15M NH<sub>4</sub>Cl, 0.01mM KHCO<sub>3</sub> and 0.1mM EDTA and resuspended in FACS buffer containing, PBS 0.5% BSA EDTA 2mM. Lungs were harvested and digested in RPMI medium (Gibco, Invitrogen, Cergy Pontoise, France) with 1mg/mL collagenase IV (Sigma) for 30min at 37°C and filtered through a 40- $\mu$ m-pore cell strainer (Becton Dickinson, Rungis, France). 1/10th of the cell suspension was incubated with 1 $\mu$ g/mL purified anti-CD16/32 (2.4G2, BD Biosciences) for 10min at 4°C then surface staining was performed by additional 20min incubation with appropriate dilution of the surface marker antibodies. Cells were then washed once in FACS buffer and analyzed directly by flow cytometry. The panel of antibodies used was: anti-CD11b (clone M1/70), anti-Ly6C (clone AL-21), anti-Ly6G (clone 1A8), anti-NK1.1 (clone PK136), , anti-IA[b] (clone AF6-120.1), anti-CD11c (clone HL3), anti-Siglec-F (clone E50-2440), anti-CD103 (clone M290), anti-CD45 (clone 30-F11), anti-CD64 (clone X54-5/7.1 ; Pharmingen, BD Bioscience), anti-FLT1 (clone 141522;R&D Systems), anti-CD206 (clone C068C2 ; Biolegend), anti-VCAM1 (clone 429; BD Biosciences). Calculation of absolute cell number was performed by adding to each vial a fixed number (10.000) of non-fluorescent 10 $\mu$ m polystyrene carboxylate microspheres (Polysciences, Niles, IL, USA) according to the formula:

$$\text{Nb of cells} = (\text{Nb of acquired cells} \times 10.000) / (\text{Nb of acquired beads}).$$
 Number of cells obtained for each sample was normalized per mg of tissue, or for the whole lungs and per mL of blood. Flow cytometry acquisition was performed on the flow cytometer FACS LSRFortessa X-20® (BD, Franklin Lakes, NJ, USA) with DIVA® Flow Cytometry software. Flow cytometry data were analyzed with FlowJo software (Tree Star, Inc, Ashland, OR, USA) and when indicated, visualized using viSNE (Amir el et al., 2013), a dimensionality reduction method which uses the Barnes-Hut acceleration of the t-SNE algorithm. viSNE was implemented using Cytobank (Chen and Kotecha, 2014).

### **Multi-photon Imaging**

Lung experiments were performed on freshly explanted tissue according to our previously work (Rodero et al., 2015). Lungs were carefully collected and were immobilized in an imaging chamber perfused with oxygenated (95% O<sub>2</sub> plus 5% CO<sub>2</sub>) RPMI medium containing 10% FCS. Local temperature was monitored and maintained at 37°C. To define the tumor vasculature 2MDa tetramethylrhodamine-Dextran (Invitrogen) was injected I.V prior to the imaging session. The Two-Photon Laser Scanning Microscopy (TPLSM) set-up used was a Zeiss 7MP (Carl Zeiss, Germany) coupled to a Ti:Sapphire Crystal multiphoton laser (Coherent ChameleonU, CA, USA) which provides 140fs pulses of NIR light, selectively tunable between 680nm and 1050nm and an optical parametric oscillator (OPO-MPX, Coherent) selectively tunable between 1050 and 1600nm. The system included a set of external non-descanned detectors in reflection with a combination of a LP-600nm followed by LP-462nm and LP-500nm dichroic mirrors to split the light and collect the SHG signal with a 417/60nm emission filter, ECFP with a 480/40nm emission filter, EGFP with a 525/50nm emission filter and tdTomato with a 624/40nm emission filter. The excitation wavelength was 850nm for the NLO beam and 1100nm for the OPO beam. Cell motility was measured every 30s by 5 consecutive 3µm z spacing stacks (total 12µm thickness) using a plan apochromat x20 (NA = 1) water immersion objective. Fluorescent cells were monitored over time with 3-dimensional automatic tracking and manual correction with Imaris software (Bitplane, Zurich,

Switzerland). The acquisition and analysis protocols for all experimental conditions to be compared were identical. Velocity and straightness were determined using Imaris. The track straightness corresponds to the ratio of the distance between the initial and the final positions of each cell to the total distance covered by the same cell. Tumor cell density analyses were performed with ImageJ software using default threshold. Data are expressed as a percent of tdTomato signal among the total surface of the tumor nodule, recorded from a z-projection of 5 consecutive 5µm z spacing stacks of the tumor nodule imaged from 40µm thick lung sections.

### **Histological analysis**

Briefly, organs were harvested and fixed in 4% PFA for 24 hours then incubated in 30% sucrose-PBS overnight at 4°C before being embedded in Tissue-Tek OCT compound (Sakura Finetek, Alphen aan den Rijn, Netherlands) and frozen at -80°C. Sectioning was completed on a HM550 Cryostat (Thermo Fisher Scientific, Waltham, MA, USA) at -20°C; 5-µm or 15 µm sections were collected on Superfrost® Plus Slides (Thermo Fisher Scientific, Waltham, MA) and stored at -20°C until use. Tissue sections were rehydrated with 0.5% Triton-PBS during 10min. A first block step was performed with 3% BSA solution during 30min followed by 1 hour incubation at 37°C with the primary antibodies Rat anti-mouse CD31 PE (clone MEC 13.3) (Becton Dickinson, San Jose, CA, USA) or the rat IgG2a, κ isotype control (clone eBR2a) (eBioscience, San Diego, CA, USA) and anti-VEGF clone B20-4.1.1 or isotype control (Genentech, San Francisco, CA, USA) and Rat anti-mouse Siglec-F PE-CF594 (clone E50-2440) were used at the appropriate dilution. The slides were then incubated with Avidin/Biotin Blocking Kit (SP-2001) (Vector Laboratories, Burlingame, CA, USA) following manufacturer protocol. Biotinylated secondary antibody binding (donkey anti-rat IgG for CD31 and Siglec-F stainings and AF647 anti-mouse IgG2a for VEGF staining, (Biolegend, San Diego, CA, USA)) was then performed during 30min at room temperature followed by Cy3-conjugated Streptavidin staining during 30min at room temperature (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Slides were

counterstained and mounted with Vectashield Mounting Medium with DAPI (4,6-diamidino-2-phenylindole; Vector Laboratories) and analysed by using Zeiss Axio Z1 fluorescent microscope (Carl Zeiss, Germany) using a Zen software. Enhanced Cyan Fluorescent Protein (ECFP), Enhanced Green Fluorescent Protein (EGFP), DAPI, Cy3 and AF647 signals were acquired using an ExBP 475/40, EmBP 530/50 for EGFP, an ExBP 436/25, EmBP 480/40 for ECFP, an ExG365, EmBP 445/50 for DAPI, an ExBP 545/25, EmBP 605/70 for Cy3 and an ExBP 640/30, EmBP 690/50 for AF647 light cube filters. Acquisition settings were identical for both isotype and CD31/VEGF staining. Cell quantification was performed by counting the number of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells using ImageJ software (National Institutes of Health).

For *Tnfr11a*<sup>Cre</sup>; *Rosa26*<sup>LSL-YFP</sup> mice, lungs images were acquired using Zeiss LSM 880 laser scanning confocal microscope. Cell quantification was performed by counting manually the number of ECFP<sup>+</sup> and EGFP<sup>+</sup> (or YFP<sup>+</sup>) cells in each field. Between 4 and 5 different fields were chosen from whole lung sections of at least 3 mice and separated according to their anatomical location. Tumor nodules located at the surface of the lung are considered in contact with the lung pleura, tumor nodules in contact with airways are easily defined by the presence of a large autofluorescent epithelial mono-layer, and tumor in the alveolar space represent all other nodules within the tumor parenchyma. All histological quantifications are presented as a mean or relative distribution of the different tumor nodules for each individual mouse.

### ***In vivo* TC-1-Luciferase cell luminescence**

*In vivo* bioluminescence imaging was conducted on the IVIS spectrum *in vivo* imaging system (Perkin Elmer, Waltham, MA, USA), using the Living Image acquisition and analysis software (Perkin Elmer, Waltham, MA, USA). Prior imaging, mice were injected with D-luciferin intraperitoneally (150mg/kg, 100μL/mouse) and anesthetized with isoflurane. The radiance from the lung region was quantified with the same software.

### **Transcriptomic analysis**

Twenty days after inoculation of TC-1 cells in MacBlue x *Cx3cr1*<sup>EGFP/+</sup>, CD11b<sup>+</sup>CD64<sup>+</sup>Ly6C<sup>-</sup> ECFP<sup>+</sup>EGFP<sup>+</sup> MoD-TAMs and CD11b<sup>+</sup>CD64<sup>+</sup>Ly6C<sup>-</sup>EGFP<sup>+</sup> resident TAMs were sorted using BD FACSAria ® (BD, Franklin Lakes, NJ, USA) with a purity > 95 %. TAMs were gated as depicted on **Figure S2A**. The two subsets were separated according to ECFP and EGFP expression. Cells were sorted from 4 independent biological replicates and total RNA was extracted using RNeasy Micro Kit (QUIAGEN) and quality was monitored with the Agilent 2100 Bioanalyser (Agilent technologies, Santa Clara, CA, USA). Each biological replicate was hybridized to Affymetrix PICO V2 MouseGene2.OST microarrays. Analysis of gene-expression profiles was performed using Multi Experiment Viewer (MeV) which provides bioinformatics tools for integrative data analysis (Saeed et al., 2006; Saeed et al., 2003). After validation of the RNA quality with Bioanalyzer 2100 (using Agilent RNA6000 nano chip kit), 2 ng of total RNA is reverse transcribed following the Ovation Pico System V2 (Nugen). Briefly, the resulting double strand cDNA is used for amplification based on SPIA technology. After purification according to Nugen protocol, 3.6µg of Sens Target DNA are fragmented and biotin labeled using Encore Biotin Module kit (Nugen). After control of fragmentation using Bioanalyzer 2100, cDNA is then hybridized to GeneChip® Mouse Gene 2.0 ST (Affymetrix) at 45°C for 17 hours. After overnight hybridization, chips are washed on the fluidic station FS450 following specific protocols (Affymetrix) and scanned using the GCS3000 7G. The scanned images are then analyzed with Expression Console software (Affymetrix) to obtain raw data (cell files) and metrics for Quality Controls. Data were normalized using RMA algorithm in Bioconductor with the custom CDF vs 21 (Nucleic Acid Research 33 (20), e175). Statistical analysis were carried out with the use of Partek® GS. First, variations in gene expression were analyzed using unsupervised hierarchical clustering and PCA to assess data from technical bias and outlier samples. 25429 genes have been identified in macrophage transcriptome. T-test was applied on EGFP<sup>+</sup> and ECFP<sup>+</sup>-macrophages transcriptomic data and we obtained 604 differentially expressed genes between these two conditions with a p-value of 0.05 based on t-distribution with overall alpha (critical p-value) and the variance assumption was welch approximation (unequal group

variances). Hierarchical Clustering was carried out on significant genes only with gene tree and sample tree then with optimized gene and sample leaf order. Pearson Correlation was the distance metric used to perform HCL, with complete linkage clustering. Data have been adjusted with median center genes/rows, median center samples/column and to the end unlog2 data transformation was applied. Within the context of biological systems Ingenuity Pathway Analysis (IPA ®) brings powerful analysis and allowed us to determine relevant bio functions and networks about the 604 differentially expressed genes.

### qRT-PCR

Fifteen days after inoculation of TC-1 cells in *Tnfrs11a<sup>Cre</sup>*; *Rosa26<sup>YFP-LSL</sup>*, YFP<sup>+</sup> TAMs and YFP<sup>-</sup> TAMs were sorted using BD FACSAria ® (BD, Franklin Lakes, NJ, USA). TAMs were gated as depicted on **Figure 3B**. 50,000 cells were directly sorted in 1mL Trizol LS reagent (ThermoFisher Scientific). RNA extraction was performed using Direct-zol RNA MicroPrep plus (Zymo research), following manufacturer's instructions. RNA concentration was measured with nanodrop2000. cDNA preparation was performed with Quantitect Reverse transcription kit (Qiagen) as per manufacturer's instructions. qRT-PCR was performed on 10ng cDNA. qRT523 PCR are performed on a Quant Studio 6 Flex using TaqMan Fast Advance Mastermix, and TaqMan probes (ThermoFisher Scientific) for Gapdh (Mm99999915\_g1), Ccl2 (Mm00441242\_m1), Cxcl13 (Mm04214185\_s1), Col14a1 (Mm00805269\_m1), Mmp8 (Mm00439509\_m1), Csf1r (Mm01266652\_m1).

### Adoptive transfer experiment

Ten days after inoculation of TC-1 cells, mice were treated with isotype control or anti-VEGF every 2 days. On day 14 after tumor inoculation, 10<sup>7</sup> bone marrow cells isolated from MacBlue mice were adoptively transferred and the recovered cells were analyzed by FACS 24 hours later.



## Statistical Analysis

All statistical analyses were performed with Graphpad Prism. Each sample values were first tested for Gaussian distribution by D'Agostino & Pearson omnibus normality test. Accordingly, multigroup analysis of variances were performed, one-way or two-way ANOVA tests followed by Bonferroni post tests for Gaussian distribution or Kruskal Wallis followed by Dunn's multiple comparisons for non-Gaussian distribution. For simple comparison analysis, Student's t-test was performed to compare parametric distribution and Mann-Whitney for non-parametric distribution. For survival curves, Log-rank (Mantel-cox) test was performed. For all pooled experiments, individual replicated were either statistically significant or showed the same trends on their own. Symbols used \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ ; \*\*\*\*:  $p < 0.0001$ ; ns=not significant.

## Online supplemental material

Fig. S1 related to Fig. 1, presents tSNE dimension 1 and 2 plots for each phenotypic marker and full gating strategy used for the study. Fig. S2, related to Fig.2, presents additional information associated with the characterization of the MacBlue x *Cx3cr1*<sup>EGFP/+</sup> model. Fig. S3, relate to Fig.4, presents additional characterization of the dynamic and distribution of macrophages subsets and the enriched function group associated with differentially regulated transcript. Fig. S4, related to Fig.3, show the impact of CP on blood monocytes, lung myeloid populations and survival in WT and *Ccr2*<sup>-/-</sup> mice. Fig. S5, related to Fig. 8 shows the expression of FLT1 in the different lung myeloid subsets and expression of VEGF in tumor nodules. Video 1 and 2 show the dynamic interactions and protrusive activities of EGFP<sup>+</sup> and ECFP<sup>+</sup> cells within tumor nodules.

## Supplemental Figure Legends

### Figure S1. Related to Figure 1: Lung macrophage subsets differentially accumulate during tumor development

(A) tSNE dimension 1 and 2 plots of the lung myeloid compartment show relative expression intensity of each indicated phenotypic marker at different time point after TC-1 cell intravenous inoculation. (B) Flow cytometry dot plots of CD45<sup>+</sup> cells show the gating strategy to discriminate lung mononuclear phagocytes in tumor-free and tumor-bearing animals. (C) Representative histogram plots show *in vivo* CD45 labelling by blood/tissue partitioning of each indicated subsets in tumor-free and tumor-bearing mice (Mean percentage $\pm$ SD of *in vivo* CD45<sup>+</sup> cells are indicated). (D) Dot plots show Ly6C and CD64 expressions by CD11b<sup>+</sup>Siglec-F<sup>-</sup>Ly6G<sup>-</sup> lung cells over time after tumor inoculation. Mean percentage $\pm$ SD of cells in each gate are indicated, n=6-8 mice per time point out 3 independent experiments.

### Figure S2. Related to Figure 2: Macrophages have distinct origins within lung tumors

(A) Lung cryo-sections from TC-1 tumor-bearing MacBlue x Cx3cr1<sup>EGFP/+</sup> show typical single channels images, Scale 50 $\mu$ m. (B) Non-supervised tSNE dimension 1 and 2 analyses indicate the myeloid cell subset clustering according to the relative expression intensity of each indicated phenotypic markers in tumor-free and TC-1 tumor-bearing MacBlue x Cx3cr1<sup>EGFP/+</sup> mice at D15. (C) Histogram plots of EGFP and ECFP expression in indicated myeloid subsets in tumor-free and TC-1 tumor-bearing MacBlue x Cx3cr1<sup>EGFP/+</sup> mice at D15. (D) Graph shows the relative proportion of EGFP<sup>+</sup> and ECFP<sup>+</sup> Ly6C<sup>low/-</sup>CD64<sup>+</sup> Mac (Bars represent mean $\pm$ SEM from 6-10 mice out of 3 independent experiments). (E) Lung cryo-sections from TC-1 tumor-bearing MacBlue x Cx3cr1<sup>EGFP/+</sup> were stained with anti-Siglec-F and show ECFP<sup>+</sup> Siglec-F<sup>+</sup> AM exclusion from tumor nodules, Scale 100 $\mu$ m (left picture), 50 $\mu$ m (right picture). For all panels \*\*: p<0.01; \*\*\*\*: p<0.0001.

### Figure S3. Related to Figure 4: Resident and MoD-TAMs harbor distinct phenotypes and anatomic distribution

(A) Time-lapse TPLSM image sequence showing the dynamic of resident EGFP<sup>+</sup> TAM interactions (dashed circles), scale 10 $\mu$ m. (B) Graph represents the relative distribution of track straightness of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells in lung tumors at day 15 and the proportion of cells above the threshold are indicated (dashed line). Bars represent mean $\pm$ SEM from 4 mice out of 2 independent experiments, Mann Whitney tests have been performed. See also video 1 and 2. (C) Lung cryo-sections from TC-1<sup>tdTomato</sup> tumor-bearing MacBlue x Cx3cr1<sup>EGFP/+</sup> show ECFP<sup>+</sup> and EGFP<sup>+</sup> cell distribution at the progressing front of lung nodules at day 20, scale 200 $\mu$ m (left picture), 50 $\mu$ m (right pictures). Graph shows quantifications of ECFP<sup>+</sup> and EGFP<sup>+</sup> cells in the tumor core or at the tumor margin. Mice are pooled from 2 independent experiments; red bars indicate means. (D) Hierarchical clustering of differentially regulated transcripts distinguishes MoD-TAMs and Res-TAMs sorted from lung tumors 20 days after TC-1 inoculation (n=4 independent cell preparation in each group, each sorting was performed from a pool of 2 to 3 mice). (E) Enriched function groups that distinguished MoD-TAMs and Res-TAMs based on Ingenuity Pathways Analysis with a p value cut-off <0.01. For all panels \*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001.

### Figure S4. Related to Figure 6: Distinct sensitivity and recovery of Res-TAMs and MoD-TAMs after chemotherapy

(A) Graphs represent the kinetic of Ly6C<sup>high</sup>-Mo and Ly6C<sup>low/-</sup>-Mo recovery in the blood, after CP treatment (Mean absolute number/ml of blood $\pm$ SEM are represented, n=6-10 mice out of 2-4 independent experiments, Two-way ANOVA with Bonferroni multiple comparisons test was performed, only statistical differences compared to day 0 after chemotherapy are indicated for each compartment). (B) Graph shows the absolute number per mg of tissue of indicated population 15 days after tumor inoculation in WT and Ccr2<sup>-/-</sup> mice treated with CP. (Bars represent mean $\pm$ SEM from 10 mice out of 3 independent experiments; Two-way

ANOVA with Bonferroni multiple comparisons test was performed). **(C)** Graph represents the monitoring of tumor growth by bioluminescence imaging after treatment in TC-1<sup>Luc</sup> tumor-bearing WT and *Ccr2*<sup>-/-</sup> mice (n=10 mice per group pooled from 2 independent experiments). **(D)** Survival curve of WT mice and *Ccr2*<sup>-/-</sup> mice after TC-1 inoculation and CP treatment (n=23-26 mice per group, pooled from 4 experiments, Log-rank (Mantel-cox) test was performed). For all panels \*: p<0.05; \*\*: p<0.01; \*\*\*\*: p<0.0001.

**Figure S5. Related to Figure 8: Anti-VEGF targets Res-TAM and MoD-TAM accumulation**

**(A)** Dot plots show the expression of FLT1 (VEGF receptor 1) on the indicated subsets. Isotype control staining is overlaid in black. Percent±SD are indicated; n=8 mice. **(B)** Lung cryo-sections from tumor-bearing MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mouse show TAM distribution regarding the expression of VEGF in tumor nodules. Anti-VEGF isotype staining is represented (right image), scale 20µm. Data are representative of 2 independent experiments

**Video Legends**


**Video 1. Related to Figure 4: Live imaging of TAM subsets in lung tumors**

3D live imaging movie shows the behaviors of EGFP<sup>+</sup> (green) and ECFP<sup>+</sup> (cyan) in explanted lung of MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mouse 15 days after tdtomato<sup>+</sup>TC-1 cells inoculation (red). Notice the dynamics of ECFP<sup>+</sup> cells (Cyan squares) and the interactions between EGFP<sup>+</sup> macrophages (White circles).

**Video 2. Related to Figure 4: Live imaging of EGFP<sup>+</sup> TAM interactions in lung tumors**

3D live imaging movie shows the dynamic protrusions (white circles) of EGFP<sup>+</sup> cells (green) in explanted lung of MacBlue x *Cx3cr1*<sup>EGFP/+</sup> mouse 15 days after TC-1 cells inoculation.

A



B




Figure 1






Figure 2



**Figure 3**










Figure 4




**Figure 5**






**Figure 6**



**Figure 7**



**Figure 8**







Figure S1. Related to Figure 1






Figure S2. Related to Figure 2





A

MacBlue ; *Cx3cr1*<sup>EGFP/+</sup>


B



C



D



E




Figure S3. Related to Figure 4






Figure S4. Related to Figure 6



**Figure S5. Related to Figure 8**